Home Merck to Present New Findings from Chronic Hepatitis C Clinical Development Programs at The International Liver CongressTM 2016
 

Keywords :   


Merck to Present New Findings from Chronic Hepatitis C Clinical Development Programs at The International Liver CongressTM 2016

2016-03-30 13:00:00| Merck.com - Research & Development News

Dateline City: KENILWORTH, N.J. Presentations Include Results from Phase 3 Study Evaluating ZEPATIER (elbasvir and grazoprevir) Compared to Sofosbuvir-Containing Regimen, and Results from Studies in Difficult-to-Treat Populations KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the planned presentations of data from the companys broad chronic hepatitis C virus (HCV) clinical development programs at the upcoming International Liver Congress 2016. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Sarra Herzog, 908-740-1871orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: international development present programs

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
05.11Boeing strike ends as workers back 38% pay rise deal
05.11Tropical Storm Rafael Public Advisory Number 6A
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Tropical Storm Rafael Graphics
05.11Atlantic Tropical Weather Outlook
05.11Eastern North Pacific Tropical Weather Outlook
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Forecast Discussion Number 6
More »